SCHEMBL4968030

SCHEMBL4968030

CCCCCCCC(=O)N(C)Cc1cccc(-c2ccc(CCC(=O)O)cc2OCC2CCCCC2)c1

nearest known ligand 0.47

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 8/20 0.41
AOC3 Q16853 3/20 0.41
THRA P10827 1/20 0.39
THRB P10828 1/20 0.39
PPARD Q03181 3/20 0.39
RXRA P19793 1/20 0.38
FFAR4 Q5NUL3 1/20 0.38
S1PR1 P21453 1/20 0.38
PTPN11 Q06124 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4974358 0.99 FFAR1 (0.42) FFAR1AOC3THRATHRBPPARD
SCHEMBL4969474 0.96 FFAR1 (0.45) FFAR1AOC3RXRAFFAR4S1PR1
SCHEMBL4969532 0.89 FFAR1 (0.44) FFAR1AOC3RXRAFFAR4PTPN11
SCHEMBL4967940 0.88 RXRA (0.47) FFAR1RXRAFFAR4PTPN11
SCHEMBL4969994 0.88 RXRA (0.47) FFAR1RXRAFFAR4PTPN11
SCHEMBL4969511 0.88 RXRA (0.47) FFAR1AOC3THRATHRBRXRA
SCHEMBL4969736 0.87 RXRA (0.44) FFAR1AOC3RXRAFFAR4PTPN11
SCHEMBL4969469 0.87 RXRA (0.47) FFAR1AOC3RXRAFFAR4PTPN11
SCHEMBL4971243 0.87 RXRA (0.47) FFAR1AOC3PPARDRXRAFFAR4
SCHEMBL4972553 0.87 FFAR1 (0.48) FFAR1FFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1781274-B1 NOVEL BIAROMATIC COMPOUNDS WHICH ACTIVATE RECEPTORS OF PPAR TYPE AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS GALDERMA RES & DEV (FR) 2008-11-05 EP claimed
US-20070207175-A1 Biaromatic compound activators of PPARgamma receptors and cosmetic/pharmaceutical compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2007-09-06 US claimed
EP-1781274-A1 NOVEL BIAROMATIC COMPOUNDS WHICH ACTIVATE RECEPTORS OF PPAR TYPE AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS Galderma Research & Development, S.N.C. (FR) 2007-05-09 EP claimed
WO-2006018325-A1 NOVEL BIAROMATIC COMPOUNDS WHICH ACTIVATE RECEPTORS OF PPAR TYPE AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2006-02-23 WO claimed
EP-1781274-B1 NOVEL BIAROMATIC COMPOUNDS WHICH ACTIVATE RECEPTORS OF PPAR TYPE AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS GALDERMA RES & DEV (FR) 2008-11-05 EP disclosed
US-20070207175-A1 Biaromatic compound activators of PPARgamma receptors and cosmetic/pharmaceutical compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2007-09-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070207175-A1 Biaromatic compound activators of PPARgamma receptors and cosmetic/pharmaceutical compositions comprised thereof PPARG, PPARA, PPARD FFAR1 13/4885AOC3 2115/4885THRA 275/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.